Christopher Porter

1 month ago | nature.com | Hope Mumme |Chenbin Huang |Denis J. Ohlstrom |Sunil Raikar |Deborah DeRyckere |Christopher Porter | +2 more

AbstractSingle-cell transcriptome profiling enables unparalleled characterization of the heterogeneous microenvironment of pediatric leukemias. To facilitate comparative analyses and generate pediatric leukemia signatures, we collect, process, and annotate single-cell data comprising over 540,000 cells from 159 different pediatric acute leukemia (myeloid, lymphoid, mixed phenotype lineages) and healthy bone marrow (BM) samples, profiled in our lab and curated from publicly available studies.

Jul 18, 2024 | nature.com | Olivier Saulnier |Paul Jerard Layug |Kimberly A Aldinger |Christopher Porter |Stephane Richard |Brad Doble | +1 more

AbstractOTX2 is a transcription factor and known driver in medulloblastoma (MB), where it is amplified in a subset of tumours and overexpressed in most cases of group 3 and group 4 MB. Here we demonstrate a noncanonical role for OTX2 in group 3 MB alternative splicing. OTX2 associates with the large assembly of splicing regulators complex through protein–protein interactions and regulates a stem cell splicing program.

Sep 19, 2023 | nature.com | Christopher Porter |Vijay Ramaswamy

AbstractSonic Hedgehog (SHH) medulloblastomas (MBs) exhibit an intermediate prognosis and extensive intertumoral heterogeneity. While SHH pathway antagonists are effective in post-pubertal patients, younger patients exhibit significant side effects, and tumors that harbor mutations in downstream SHH pathway genes will be drug resistant. Thus, novel targeted therapies are needed.